Skip to main content

The Boston Institute of Biotechnology boasts the world’s inaugural ultra-large bioreactor, featuring an impressive 30,000L working volume capacity and a total volume exceeding 40,000L. This cutting-edge bioreactor represents a pivotal advancement in the field, strategically designed to significantly reduce costs and accelerate time-to-market. Our mission is to transform your molecular innovations into impactful medicines, addressing the critical needs of patients.

Recently, we successfully concluded Phase 3 (P03) of our expansive Contract Development and Manufacturing Organization (CDMO) facility dedicated to biologics. This state-of-the-art facility boasts a remarkable total capacity exceeding 200,000 liters. The project spans a vast construction area of 123,700 square meters, featuring the world’s largest stainless steel mammalian cell production line, equipped with a 30,000L working volume capacity.

At the helm of BIB are visionary founders and core executives who bring forth a wealth of expertise from the world’s leading biopharmaceutical CDMO companies. With an average of over 20 years of industrial experience each, our team has successfully executed over 162 projects in biopharmaceutical manufacturing, spanning research and development, production, and operations within globally-regulated markets. Notably, BIB employs an innovative and disruptive PanFlex-Engineering system, enabling the construction of biopharmaceutical production sites in half the time and cost of comparable developments. In addition, our quality system meets the requirements from FDA, EMA, PMDA and China NMPA.

For those seeking to revolutionize their therapeutics manufacturing and development, we invite you to contact us today. At BIB, we are dedicated to pioneering advancements that shape the future of biopharmaceuticals.

Please send business inquiries to: contactus@bostonbib.com

Click to rate this post!
[Total: 1 Average: 5]

Author Jay Berube

More posts by Jay Berube